Scholarlink

Purpose <p>Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet cancer-related fatigue (CRF) remains a frequent but poorly characterized adverse effect. We evaluated CRF incidence during ICI treatment in neoadjuvant and adjuvant settings.</p> Methods <p>We conducted a systematic review of prospective cohort studies and phase 2 or higher trials investigating FDA-approved ICIs in adjuvant or neoadjuvant settings, reporting fatigue as an adverse event or via patient-reported outcomes (PROs). Searches conducted across four databases and ClinicalTrials.gov through September 2024 followed PRISMA guidelines using Covidence software. Studies not in English, lacking full text, or insufficient for meta-analysis were excluded. Data on fatigue incidence and quality of life were extracted. Risk of bias was assessed using the Cochrane tool, and certainty of evidence was graded using GRADEPro. Meta-analysis was performed on all included studies.</p> Results <p>Forty-three studies met inclusion criteria, primarily involving melanoma, breast, lung, renal, and gastroesophageal cancers. Common ICIs included nivolumab, pembrolizumab, ipilimumab, and durvalumab. Fatigue was more frequent with ICIs versus placebo (risk ratio [RR] 1.21, 95% CI 1.08–1.35), and PROs indicated higher fatigue levels (standardized mean difference 0.12, 95% CI 0.01–0.23). No significant difference was observed between ICIs and chemotherapy (RR 0.81, 95% CI 0.36–1.82). Risk of bias was high due to allocation concealment and open-label designs.</p> Conclusions <p>ICI monotherapy is associated with modestly increased CRF compared with placebo, as reported by clinicians and patients. These findings underscore the need for patient counseling and further research on the severity and trajectory of ICI-related CRF.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cancer-related fatigue during treatment with neoadjuvant and/or adjuvant immune checkpoint inhibitors: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Lucy Potter,
  • Maria A. Lopez-Olivo,
  • Rajdeep Singh Uppal,
  • Dori Beeler,
  • Melissa S. Y. Thong,
  • Brandy Phan,
  • Yun-Jen Chou,
  • Kate Krause,
  • Areesha Tanveer,
  • Hassan Ul Hussain,
  • Muaaz Khan,
  • Noha Abdel-Wahab,
  • Ellen Manzullo,
  • Amber S. Kleckner,
  • Carmen Escalante

摘要

Purpose

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet cancer-related fatigue (CRF) remains a frequent but poorly characterized adverse effect. We evaluated CRF incidence during ICI treatment in neoadjuvant and adjuvant settings.

Methods

We conducted a systematic review of prospective cohort studies and phase 2 or higher trials investigating FDA-approved ICIs in adjuvant or neoadjuvant settings, reporting fatigue as an adverse event or via patient-reported outcomes (PROs). Searches conducted across four databases and ClinicalTrials.gov through September 2024 followed PRISMA guidelines using Covidence software. Studies not in English, lacking full text, or insufficient for meta-analysis were excluded. Data on fatigue incidence and quality of life were extracted. Risk of bias was assessed using the Cochrane tool, and certainty of evidence was graded using GRADEPro. Meta-analysis was performed on all included studies.

Results

Forty-three studies met inclusion criteria, primarily involving melanoma, breast, lung, renal, and gastroesophageal cancers. Common ICIs included nivolumab, pembrolizumab, ipilimumab, and durvalumab. Fatigue was more frequent with ICIs versus placebo (risk ratio [RR] 1.21, 95% CI 1.08–1.35), and PROs indicated higher fatigue levels (standardized mean difference 0.12, 95% CI 0.01–0.23). No significant difference was observed between ICIs and chemotherapy (RR 0.81, 95% CI 0.36–1.82). Risk of bias was high due to allocation concealment and open-label designs.

Conclusions

ICI monotherapy is associated with modestly increased CRF compared with placebo, as reported by clinicians and patients. These findings underscore the need for patient counseling and further research on the severity and trajectory of ICI-related CRF.